BRAF V600E mutations: A series of case reports in patients with non-small cell lung cancer

Cancer Genetics

Volumn 208, Issue 6, 2015, Pages 351-354

  Goldman, Jamie M ^a   Gray, Jhanelle E ^b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Adenocarcinoma; BRAF; Driver mutations; Non small cell lung cancer; V600E

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE; BEVACIZUMAB; CARBOPLATIN; DNA; ERLOTINIB; GEMCITABINE; HEAT SHOCK PROTEIN 90 INHIBITOR; PACLITAXEL; PEMETREXED; BRAF PROTEIN, HUMAN;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; AVASCULAR NECROSIS; BRAIN METASTASIS; BRAIN RADIATION; BREAST CANCER; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DEATH; DNA EXTRACTION; DRUG WITHDRAWAL; DYSARTHRIA; DYSPHAGIA; EDEMA; ESOPHAGEAL ADENOCARCINOMA; FACIAL DROOPING; FACIAL NERVE PARALYSIS; FEMALE; FINE NEEDLE ASPIRATION BIOPSY; GENE AMPLIFICATION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KNEE DISEASE; LUNG ADENOCARCINOMA; LUNG BIOPSY; LUNG LOBECTOMY; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; MEDIASTINOSCOPY; MICRODISSECTION; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; MUTATIONAL ANALYSIS; NON SMALL CELL LUNG CANCER; POLYMERASE CHAIN REACTION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEINURIA; SEX DIFFERENCE; SMOKING; SPEECH DISORDER; SQUAMOUS CELL LUNG CARCINOMA; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; WEAKNESS; ADENOCARCINOMA; ADVERSE EFFECTS; BREAST TUMOR; CASE REPORT; GENETICS; LUNG TUMOR; SQUAMOUS CELL CARCINOMA;

ADENOCARCINOMA; AGED; BREAST NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS B-RAF; SMOKING;

EID: 84937975876     PISSN: 22107762     EISSN: 22107770     Source Type: Journal    
DOI: 10.1016/j.cancergen.2015.04.001     Document Type: Article

References (30)

1. Pao W., Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol 2011, 12:175-180.
2. Reungwetwattana T., Weroha S.J., Molina J.R. Oncogenic pathways, molecularly targeted therapies, and highlighted clinical trials in non-small-cell lung cancer (NSCLC). Clin Lung Cancer 2012, 13:252-266.
3. Jemal A., Siegel R., Xu J., et al. Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
4. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013, 63:11-30.
5. Han Y., Yu D.P., Zhou S.J., et al. Associations between clinical characteristics and oncogene expression in patients with non-small cell lung cancer. Genet Mol Res 2014, 13:8913-8924.
6. Chen D., Zhang L.Q., Huang J.F., et al. BRAF mutations in patients with non-small cell lung cancer: a systematic review and meta-analysis. PLoS One 2014, 9:e101354.
7. Corcoran R.B., Ebi H., Turke A.B., et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov 2012, 2:227-235.
8. Paik P.K., Arcila M.E., Fara M., et al. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. JClin Oncol 2011, 29:2046-2051.
9. Kris M.G., Johnson B.E., Berry L.D., et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 2014, 311:1998-2006.
10. Prahallad A., Sun C., Huang S., et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012, 483:100-103.
11. Kinno T., Tsuta K., Shiraishi K., et al. Clinicopathological features of nonsmall cell lung carcinomas with BRAF mutations. Ann Oncol 2014, 25:138-142.
12. Marchetti A., Felicioni L., Malatesta S., et al. Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. JClin Oncol 2011, 29:3574-3579.
13. Lin L., Asthana S., Chan E., et al. Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer. Proc Natl Acad Sci U S A 2014, 111:E748-E757.
14. Langaee T., Ronaghi M. Genetic variation analyses by pyrosequencing. Mutat Res 2005, 573:96-102.
15. Dufort S., Richard M.J., de Fraipont F. Pyrosequencing method to detect KRAS mutation in formalin-fixed and paraffin-embedded tumor tissues. Anal Biochem 2009, 391:166-168.
16. Sequist L.V., Heist R.S., Shaw A.T., et al. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Ann Oncol 2011, 22:2616-2624.
17. Su Z., Dias-Santagata D., Duke M., et al. Aplatform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer. JMol Diagn 2011, 13:74-84.
18. Cardarella S., Ogino A., Nishino M., et al. Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer. Clin Cancer Res 2013, 19:4532-4540.
19. Zhang Q., Wang J., Wang F., et al. Identification of type II inhibitors targeting BRAF using privileged pharmacophores. Chem Biol Drug Des 2014, 83:27-36.
20. Chang F., Steelman L.S., Lee J.T., et al. Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention. Leukemia 2003, 17:1263-1293.
21. Smit E. BRAF mutations in non-small-cell lung cancer. JThorac Oncol 2014, 9:1594-1595.
22. Hall R.D., Kudchadkar R.R. BRAF mutations: signaling, epidemiology, and clinical experience in multiple malignancies. Cancer Control 2014, 21:221-230.
23. Genentech. FDA approves Zelboraf (vemurafenib) and companion diagnostic for BRAF mutation-positive metastatic melanoma, a deadly form of skin cancer. Available at: . Accessed November 27, 2013. http://www.roche.com/media/store/releases/med-cor-2011-08-17.htm.
24. Bollag G., Tsai J., Zhang J., et al. Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat Rev Drug Discov 2012, 11:873-886.
25. Sosman J.A., Kim K.B., Schuchter L., et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. NEngl J Med 2012, 366:707-714.
26. Chapman P.B., Hauschild A., Robert C., et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. NEngl J Med 2011, 364:2507-2516.
27. Millington G.W. Mutations of the BRAF gene in human cancer, by Davies etal. (Nature 2002; 417: 949-954). Clin Exp Dermatol 2013, 38:222-223.
28. Planchard D, Mazieres J, Riely GJ, etal. Interim results of phase II study BRF113928 of dabrafenib in BRAF V600E mutation-positive non-small cell lung cancer (NSCLC) patients. J Clin Oncol, 2013 ASCO Annual Meeting Abstracts 2013;31.
29. El-Osta H., Falchook G., Tsimberidou A., et al. BRAF mutations in advanced cancers: clinical characteristics and outcomes. PLoS One 2011, 6:e25806.
30. Yousem S.A., Nikiforova M., Nikiforov Y. The histopathology of BRAF-V600E-mutated lung adenocarcinoma. Am J Surg Pathol 2008, 32:1317-1321.